Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models

E Huarte, M Peel, L Stephens, B Stewart, B Long, P Czerniak, J Oliver and P Smith are employees and stockholders of Incyte. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Editorial assistance was provided by Envision Pharma Group, Inc., (Philadelphia, PA, USA), and funded by Incyte Corporation (Wilmington, DE, USA).

留言 (0)

沒有登入
gif